Clinical Biomarkers - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, Application, End User, and Region - Analysis and Forecast, 2022-2032
Description
Clinical Biomarkers - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, Application, End User, and Region - Analysis and Forecast, 2022-2032
Global Clinical Biomarkers Market Industry Overview
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.
Market Lifecycle Stage
Clinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition. Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.
Impact
The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.
The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.
Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers. The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.
Market Segmentation:
Segmentation 1: by Offering
Segmentation 2: by Technology
Segmentation 3: by Application
Segmentation 4: Clinical Area
Segmentation 5: by End User
Segmentation 6: by Region
Following are the demand drivers for the clinical biomarkers market:
Product/Innovation Strategy: Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.
Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
PDF email from publisher allows for 1-3 users, with permission to print*
Global Clinical Biomarkers Market Industry Overview
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.
Market Lifecycle Stage
Clinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition. Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.
Impact
- Increasing demand for clinical biomarkers products is anticipated to support the growth of the global clinical biomarkers market during the forecast period 2022-2032.
- The market is expected to grow at a significant growth rate due to opportunities such as the expansion of biomarker discovery and increased research funding for executing research and development exercises.
The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.
The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.
Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers. The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.
Market Segmentation:
Segmentation 1: by Offering
- Product
- Service
Segmentation 2: by Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Other Technologies
Segmentation 3: by Application
- Clinical Diagnostic
- Translational Research
Segmentation 4: Clinical Area
- Cancer Biomarker
- Cardiac Biomarker
- Neurological Biomarker
- Infectious Disease Biomarker
- Immunological Biomarker
- Non-Invasive Prenatal Testing
- Other Clinical Areas
Segmentation 5: by End User
- Contract Research Organizations (CROs)
- Research and Academic Laboratories
- Biopharmaceutical and Biotech Companies
- Diagnostic Centers
- Other End Users
Segmentation 6: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World The North America region is expected to dominate the global clinical biomarkers market during the forecast period 2022-2032. North America has a high adoption rate of cancer genomics research. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.
- Acquisition in 2021: NeoGenomics Laboratories acquired Inivata. With this acquisition, the company strengthened its market position and expanded its footprint in the clinical biomarkers market.
- Collaboration: In 2022, F. Hoffmann-La Roche Ltd collaborated with Nordic Bioscience to strengthen the development of biomarkers for chronic diseases.
- Product Approval: In 2020, F. Hoffmann-La Roche Ltd received FDA approval for an assay to detect the HER2 biomarker in breast cancer.
Following are the demand drivers for the clinical biomarkers market:
- Increasing Demand for Clinical Biomarker Products
- Increasing Key Player Initiatives
- Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
- Higher Price of Product/Service Hampering the Expansion in Low-Income countries
- Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
- Lack of Qualified Professionals
Product/Innovation Strategy: Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.
Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
- Abbott.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- PerkinElmer Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- NeoGenomics Laboratories
- Charles River Laboratories
- F. Hoffmann-La Roche Ltd
- Quest Diagnostics Incorporated
- Enzo Biochem Inc.
- ALCEN
- Myriad Genetics, Inc.
- CENTOGENE N.V.
- bioMérieux S.A.
- Arsenal Capital Partners
- Novogene Co., Ltd.
- Q2 Solutions
- Caris Life Sciences
- Broad Institute
- Personalis Inc.
- Azenta Life Sciences
- Discovery Life Sciences(DLS)
- BGI
- Eurofins Scientific
- Becton, Dickinson and Company
PDF email from publisher allows for 1-3 users, with permission to print*
Table of Contents
254 Pages
- 1 Market
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion
- 2 Market Scope
- 2.1 Key Questions Answered in the Report
- 3 Research Methodology
- 3.1 Data Sources
- 3.1.1 Primary Data Source
- 3.1.2 Secondary Data Sources
- 3.1.2.1 Open Sources
- 3.2 Market Estimation Model
- 3.3 Criteria for Company Profiling
- 4 Market Overview
- 4.1 Introduction
- 4.2 Clinical Biomarkers Approaches in Precision Medicine
- 4.3 Market Size Potential for Clinical Biomarkers, 2021-2032
- 4.4 COVID-19 Impact on Global Clinical Biomarkers Market
- 4.4.1 Impact on Market Size
- 5 Market Dynamics
- 5.1 Impact Analysis
- 5.2 Market Drivers
- 5.2.1 Increasing Demand for Clinical Biomarker Products
- 5.2.2 Rising Key Player Initiatives
- 5.2.3 Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
- 5.3 Market Challenges
- 5.3.1 Higher Price of Product/Service Hampering the Expansion in Low-Income countries
- 5.3.2 Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
- 5.3.3 Lack of Qualified Professionals
- 5.4 Market Opportunities
- 5.4.1 Technological Advancement in Biomarker Discovery
- 5.4.2 Increased Research Funding for Executing Research and Development Exercise
- 6 Industry Insights
- 6.1 Regulatory Framework
- 6.1.1 Regulatory Framework in the U.S
- 6.1.2 FDA Regulations
- 6.1.3 Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff
- 6.1.4 Regulatory Framework in the U.S. for Medical Devices
- 6.1.5 Legal Requirements and Framework in Europe
- 6.1.5.1 U.K.
- 6.1.5.2 Germany
- 6.1.6 Legal Requirements and Framework in Asia-Pacific
- 6.1.6.1 China
- 6.1.6.2 Japan
- 6.1.6.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
- 6.2 Patent Analysis
- 7 Competitive Insights
- 7.1 Corporate Strategies
- 7.1.1 Acquisitions
- 7.1.2 Synergistic Activities
- 7.1.3 Funding and Business Expansions
- 7.2 Business Strategies
- 7.2.1 Service/Product Launches
- 7.3 Supply Chain Analysis
- 7.4 Pricing Analysis
- 7.4.1 Pricing Analysis by Product
- 7.4.2 Pricing Analysis by Testing Services
- 7.5 Market Share Analysis (by Product Manufacturer)
- 7.6 Market Share Analysis (by Service Provider)
- 7.7 Growth-Share Analysis (by Product Manufacturer)
- 7.8 Growth-Share Analysis (by Service Provider)
- 7.9 Growth-Share Analysis (Application)
- 7.1 Growth-Share Analysis (End User)
- 8 Global Clinical biomarkers market, by Offering, $Million, 2021-2032
- 8.1 Overview
- 8.2 Product
- 8.2.1 Efficacy Biomarker
- 8.2.1.1 Diagnostic Biomarker
- 8.2.1.2 Predictive Biomarker
- 8.2.1.3 Prognostic Biomarker
- 8.2.2 Safety Biomarker
- 8.2.3 Validation Biomarker
- 8.3 Service
- 8.3.1 Genomic Biomarker Service
- 8.3.2 Tissue Biomarker Service
- 8.3.3 Cell Service
- 8.3.4 Proteomics Service
- 9 Global Clinical biomarkers market, by Technology, $Million, 2021-2032
- 9.1 Overview
- 9.2 Next-Generation Sequencing (NGS)
- 9.3 Polymerase Chain Reaction (PCR)
- 9.4 Immunohistochemistry (IHC)
- 9.5 Enzyme-Linked Immunosorbent Assay (ELISA)
- 9.6 Other Technologies
- 10 Global Clinical Biomarkers Market, by Clinical Area, $Million, 2021-2032
- 10.1 Overview
- 10.2 Cancer Biomarker
- 10.2.1 Breast Cancer Biomarker
- 10.2.2 Lung Cancer Biomarker
- 10.2.3 Colorectal Cancer Biomarker
- 10.2.4 Prostate Cancer Biomarker
- 10.2.5 Other
- 10.3 Cardiac Biomarker
- 10.4 Neurological Biomarker
- 10.5 Infectious Disease Biomarker
- 10.6 Non-Invasive Prenatal Testing
- 10.7 Immunological Biomarker
- 10.8 Other Clinical Areas
- 11 Global Clinical biomarkers Market, by Application, $Million, 2021-2032
- 11.1 Overview
- 11.1.1 Translational Research
- 11.1.2 Clinical Diagnostic
- 12 Global Clinical Biomarkers Market, by End User, $Million, 2021-2032
- 12.1 Overview
- 12.1.1 Contract Research Organizations (CROs)
- 12.1.2 Research and Academic Laboratories
- 12.1.3 Diagnostic Centers
- 12.1.4 Biopharmaceutical and Biotech Companies
- 12.1.5 Other End Users
- 13 Region
- 13.1 Overview
- 13.2 North America
- 13.2.1 U.S.
- 13.2.2 Canada
- 13.3 Europe
- 13.3.1 Germany
- 13.3.2 France
- 13.3.3 U.K.
- 13.3.4 Italy
- 13.3.5 Spain
- 13.3.6 Rest-of-Europe
- 13.4 Asia-Pacific
- 13.4.1 China
- 13.4.2 India
- 13.4.3 Japan
- 13.4.4 South Korea
- 13.4.5 Australia
- 13.4.6 Rest-of-Asia-Pacific
- 13.5 Latin America
- 13.5.1 Brazil
- 13.5.2 Mexico
- 13.5.3 Rest-of-Latin America
- 13.6 Rest-of-the-World
- 14 Market - Company Profiles
- 14.1 Overview
- 14.2 Abbott.
- 14.2.1 Company Overview
- 14.2.2 Role of Abbott. in the Global Clinical Biomarkers Market
- 14.2.3 Key Competitors of the Company
- 14.2.4 Corporate Strategies
- 14.2.5 Business Strategies
- 14.2.6 Financials
- 14.2.7 Key Insights about the Financial Health of the Company
- 14.2.8 Analyst’s Perspective
- 14.3 Agilent Technologies, Inc.
- 14.3.1 Company Overview
- 14.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
- 14.3.3 Key Competitors of the Company
- 14.3.4 Corporate Strategies
- 14.3.5 Financials
- 14.3.6 Key Insights about the Financial Health of the Company
- 14.3.7 Analyst’s Perspective
- 14.4 Bio-Rad Laboratories, Inc.
- 14.4.1 Company Overview
- 14.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
- 14.4.3 Key Competitors of the Company
- 14.4.4 Financials
- 14.4.5 Key Insights about the Financial Health of the Company
- 14.4.6 Analyst’s Perspective
- 14.5 Illumina, Inc.
- 14.5.1 Company Overview
- 14.5.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market
- 14.5.3 Key Competitors of the Company
- 14.5.1 Corporate Strategies
- 14.5.2 Financials
- 14.5.3 Key Insights about the Financial Health of the Company
- 14.5.4 Analyst’s Perspective
- 14.6 PerkinElmer Inc.
- 14.6.1 Company Overview
- 14.6.2 Role of PerkinElmer Inc. in the Global Clinical Biomarkers Market
- 14.6.3 Key Competitors of the Company
- 14.6.4 Financials
- 14.6.5 Key Insights about the Financial Health of the Company
- 14.6.6 Analyst’s Perspective
- 14.7 QIAGEN N.V.
- 14.7.1 Company Overview
- 14.7.2 Role of QIAGEN N.V. in the Global Clinical Biomarkers Market
- 14.7.3 Key Competitors of the Company
- 14.7.4 Key Customers of the Company
- 14.7.5 Corporate Strategies
- 14.7.6 Business Strategies
- 14.7.7 Financials
- 14.7.8 Key Insights about the Financial Health of the Company
- 14.7.9 Analyst’s Perspective
- 14.8 Thermo Fisher Scientific Inc.
- 14.8.1 Company Overview
- 14.8.2 Role of Thermo Fisher Scientific Inc. in the Global Clinical Biomarkers Market
- 14.8.3 Key Competitors of the Company
- 14.8.4 Business Strategies
- 14.8.5 Corporate Strategies
- 14.8.6 Financials
- 14.8.7 Key Insights about the Financial Health of the Company
- 14.8.8 Analyst’s Perspective
- 14.9 NeoGenomics Laboratories
- 14.9.1 Company Overview
- 14.9.2 Role of NeoGenomics Laboratories in the Global Clinical Biomarkers Market
- 14.9.3 Key Competitors of the Company
- 14.9.4 Key Customers of the Company
- 14.9.5 Business Strategies
- 14.9.6 Financials
- 14.9.7 Key Insights about the Financial Health of the Company
- 14.9.8 Analyst’s Perspective
- 14.1 Charles River Laboratories
- 14.10.1 Company Overview
- 14.10.2 Role of Charles River Laboratories in the Global Clinical Biomarkers Market
- 14.10.3 Financials
- 14.10.4 Analyst’s Perspective
- 14.11 F. Hoffmann-La Roche Ltd
- 14.11.1 Company Overview
- 14.11.2 Role of F. Hoffmann-La Roche Ltd in the Global Clinical Biomarkers Market
- 14.11.3 Key Competitors of the Company
- 14.11.4 Business Strategies
- 14.11.5 Corporate Strategies
- 14.11.6 Financials
- 14.11.7 Key Insights about the Financial Health of the Company
- 14.11.8 Analyst’s Perspective
- 14.12 Quest Diagnostics Incorporated
- 14.12.1 Company Overview
- 14.12.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
- 14.12.3 Key Competitors of the Company
- 14.12.4 Financials
- 14.12.5 Analyst Perspective
- 14.13 Enzo Biochem Inc.
- 14.13.1 Company Overview
- 14.13.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
- 14.13.3 Key Competitors of the Company
- 14.13.4 Financials
- 14.13.5 Key Insights about the Financial Health of the Company
- 14.13.6 Analyst’s Perspective
- 14.14 ALCEN
- 14.14.1 Company Overview
- 14.14.2 Role of ALCEN in Global Clinical Biomarkers Market
- 14.14.3 Analyst’s Perspective
- 14.15 Myriad Genetics, Inc.
- 14.15.1 Company Overview
- 14.15.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
- 14.15.3 Corporate Strategies
- 14.15.4 Financials
- 14.15.5 Key Insights about the Financial Health of the Company
- 14.15.6 Analyst’s Perspective
- 14.16 CENTOGENE N.V.
- 14.16.1 Company Overview
- 14.16.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
- 14.16.3 Business Strategies
- 14.16.4 Financials
- 14.16.5 Key Insights about the Financial Health of the Company
- 14.16.6 Analyst’s Perspective
- 14.17 bioMérieux S.A.
- 14.17.1 Company Overview
- 14.17.2 Role of bioMérieux S.A. in the Global Clinical Biomarkers Market
- 14.17.3 Corporate Strategies
- 14.17.4 Business Strategies
- 14.17.5 Financials
- 14.17.6 Analyst’s Perspective
- 14.18 Arsenal Capital Partners
- 14.18.1 Company Overview
- 14.18.2 Role of Arsenal Capital Partners in the Global Clinical Biomarkers Market
- 14.18.3 Business Strategies
- 14.18.4 Analyst’s Perspective
- 14.19 Novogene Co., Ltd.
- 14.19.1 Company Overview
- 14.19.2 Role of Novogene Co., Ltd. in the Global Clinical Biomarkers Market
- 14.19.3 Analyst’s Perspective
- 14.2 Q2 Solutions
- 14.20.1 Company Overview
- 14.20.2 Role of Q2 Solutions in the Global Clinical Biomarkers Market
- 14.20.3 Business Strategies
- 14.20.4 Analyst’s Perspective
- 14.21 Caris Life Sciences
- 14.21.1 Company Overview
- 14.21.2 Role of Caris Life Sciences in the Global Clinical Biomarkers Market
- 14.21.3 Analyst’s Perspective
- 14.22 Broad Institute
- 14.22.1 Company Overview
- 14.22.2 Role of Broad Institute in the Global Clinical Biomarkers Market
- 14.22.3 Analyst’s Perspective
- 14.23 Personalis Inc.
- 14.23.1 Company Overview
- 14.23.2 Role of Personalis Inc. in the Global Clinical Biomarkers Market
- 14.23.3 Key Competitors of the Company
- 14.23.4 Key Customers of the Company
- 14.23.5 Business Strategies
- 14.23.6 Corporate Strategies
- 14.23.7 Financials
- 14.23.8 Key Insights about the Financial Health of the Company
- 14.23.9 Analyst’s Perspective
- 14.24 Azenta Life Sciences
- 14.24.1 Company Overview
- 14.24.2 Role of Azenta Life Sciences in the Global Clinical Biomarkers Market
- 14.24.3 Business Strategies
- 14.24.4 Analyst’s Perspectives
- 14.25 Discovery Life Sciences(DLS)
- 14.25.1 Company Overview
- 14.25.2 Role of Discovery Life Sciences in the Global Clinical Biomarkers Market
- 14.25.3 Key Partners
- 14.25.4 Business Strategies
- 14.25.5 Analyst’s Perspective
- 14.26 BGI
- 14.26.1 Company Overview
- 14.26.2 Role of BGI in Global Clinical Biomarkers Market
- 14.26.3 Corporate Strategies
- 14.26.4 Analyst’s Perspective
- 14.27 Eurofins Scientific
- 14.27.1 Company Overview
- 14.27.2 Role of Eurofins Scientific in the Global Clinical Biomarkers Market
- 14.27.3 Key Competitors of the Company
- 14.27.4 Corporate Strategies
- 14.27.5 Financials
- 14.27.6 Analyst’s Perspective
- 14.28 Becton, Dickinson and Company
- 14.28.1 Company Overview
- 14.28.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
- 14.28.3 Financials
- 14.28.4 Key Insights about the Financial Health of the Company
- 14.28.5 Analyst’s Perspective
- List of Figures
- Figure 1: Global Clinical Biomarkers Market Dynamics
- Figure 2: Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032
- Figure 3: Global Clinical Biomarkers Market (by Application), $Million, 2021 and 2032
- Figure 4: Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032
- Figure 5: Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032
- Figure 6: Global Clinical Biomarkers Market (by End User), $Million, 2021 and 2032
- Figure 7: Global Clinical Biomarkers Market (by Region), $Million, 2021
- Figure 8: Global Clinical Biomarkers Market Research Methodology
- Figure 9: Primary Research Methodology
- Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 11: Top-Down Approach (Segment-Wise Analysis)
- Figure 12: Biomarkers Used in Various Clinical Areas
- Figure 13: Leading Segments of the Global Clinical Biomarkers Market, 2021 and 2032
- Figure 14: Global Clinical Biomarkers Market, $Million, 2021-2032
- Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Clinical Biomarkers Market, $Million, 2019-2025
- Figure 16: Impact of COVID-19 on Clinical Biomarkers Market
- Figure 17: Global Clinical Biomarkers Market Dynamics
- Figure 18: Percentage of People Reporting Chronic Lower Respiratory Diseases in Europe Region, 2019
- Figure 19: Cancer Cases in U.S., 2021
- Figure 20: NIH Funding, 2019-2022
- Figure 21: Responsibilities of the National Medical Products Administration (NMPA)
- Figure 22: Synergistic Activities Share (by Company), January 2019-July 2022
- Figure 23: Funding and Business Expansions (by Company), January 2019-July 2022
- Figure 24: Service/Product Launches (by Key Companies), January 2019-July 2022
- Figure 25: Clinical Biomarkers Supply Chain Analysis
- Figure 26: Global Clinical Biomarkers Market Share Analysis (by Product Manufacturer), 2020 and 2021
- Figure 27: Global Clinical Biomarkers Market Share Analysis (by Service Provider), 2020 and 2021
- Figure 28: Growth-Share Analysis for Global Clinical Biomarkers Market (by Product Manufacturer)
- Figure 29: Growth-Share Analysis for Global Clinical Biomarkers Market (by Service Provider)
- Figure 30: Growth Share Analysis for Global Clinical Biomarkers Market (by Application), 2021-2032
- Figure 31: Growth Share Analysis for Global Clinical Biomarkers Market (by End User), 2021-2032
- Figure 32: Global Clinical Biomarkers Market (by Offering)
- Figure 33: Share of Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032
- Figure 34: Share of Global Clinical Biomarkers Market (by Product), $Million, 2021 and 2032
- Figure 35: Global Clinical Biomarkers Market (Product), $Million, 2021-2032
- Figure 36: Global Clinical Biomarkers Market (Efficacy Biomarker), $Million, 2021-2032
- Figure 37: Global Clinical Biomarkers Market (Diagnostic Biomarker), $Million, 2021-2032
- Figure 38: Role and Example of Predictive Biomarker
- Figure 39: Global Clinical Biomarkers Market (Predictive Biomarker), $Million, 2021-2032
- Figure 40: Global Clinical Biomarkers Market (Prognostic Biomarker), $Million, 2021-2032
- Figure 41: Global Clinical Biomarkers Market (Safety Biomarker), $Million, 2021-2032
- Figure 42: Global Clinical Biomarkers Market (Validation Biomarker), $Million, 2021-2032
- Figure 43: Share of Global Clinical Biomarkers Market (by Service), $Million, 2021 and 2032
- Figure 44: Global Clinical Biomarkers Market (Service), $Million, 2021-2032
- Figure 45: Global Clinical Biomarkers Market (Genomic Biomarker Service), $Million, 2021-2032
- Figure 46: Global Clinical Biomarkers Market (Tissue Biomarker Service), $Million, 2021-2032
- Figure 47: Global Clinical Biomarkers Market (Cell Service), $Million, 2021-2032
- Figure 48: Global Clinical Biomarkers Market (Proteomics Service), $Million, 2021-2032
- Figure 49: Global Clinical Biomarkers Market (by Technology)
- Figure 50: Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032
- Figure 51: Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
- Figure 52: Global Clinical Biomarkers market (Next-Generation Sequencing), $Million, 2021-2032
- Figure 53: Global Next-Generation Sequencing Market (Service), $Million, 2021-2032
- Figure 54: Application of PCR
- Figure 55: Global Clinical Biomarkers Market (Polymerase Chain Reaction), $Million, 2021-2032
- Figure 56: Global Polymerase Chain Reaction Market (Service), $Million, 2021-2032
- Figure 57: Global Clinical Biomarkers Market (Immunohistochemistry (IHC)), $Million, 2021-2032
- Figure 58: Global Immunohistochemistry (IHC) Market (Service), $Million, 2021-2032
- Figure 59: Global Clinical Biomarkers Market Enzyme-Linked Immunosorbent Assay (ELISA)), $Million, 2021-2032
- Figure 60: Global Enzyme-Linked Immunosorbent assay (ELISA) Market (Service), $Million, 2021-2032
- Figure 61: Global Clinical Biomarkers Market (Other Technologies), $Million, 2021-2032
- Figure 62: Global Other Technology Market (Service), $Million, 2021-2032
- Figure 63: Global Clinical Biomarkers Market (by Clinical Area)
- Figure 64: Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032
- Figure 65: Global Clinical Biomarkers Market (Cancer Biomarker), $Million, 2021-2032
- Figure 66: Global Clinical Biomarkers Market (Breast Cancer Biomarker), $Million, 2021-2032
- Figure 67: Global Clinical Biomarkers Market (Lung Cancer Biomarker), $Million, 2021-2032
- Figure 68: Global Clinical Biomarkers Market (Colorectal Cancer Biomarker), $Million, 2021-2032
- Figure 69: Global Clinical Biomarkers Market (Prostate Cancer Biomarker), $Million, 2021-2032
- Figure 70: Global Clinical Biomarkers Market (Other), $Million, 2021-2032
- Figure 71: Global Clinical Biomarkers Market (Cardiac Biomarker), $Million, 2021-2032
- Figure 72: Global Clinical Biomarkers Market (Neurological Biomarker), $Million, 2021-2032
- Figure 73: Global Clinical Biomarkers Market (Infectious Disease Biomarker), $Million, 2021-2032
- Figure 74: Global Clinical Biomarkers Market Non-Invasive Prenatal Testing (NIPT)), $Million, 2021-2032
- Figure 75: Global Clinical Biomarkers Market (Immunological Biomarker), $Million, 2021-2032
- Figure 76: Global Clinical Biomarkers market (Other Clinical Areas), $Million, 2021-2032
- Figure 77: Global Clinical Biomarkers Market (by Application)
- Figure 78: Global Clinical Biomarkers Market (by Application), 2021 vs. 2032
- Figure 79: Global Clinical Biomarkers Market (Translational Research), $Million, 2021-2032
- Figure 80: Global Clinical Biomarkers Market (Clinical Diagnostic), $Million, 2021-2032
- Figure 81: Global Clinical Biomarkers Market (by End User), 2021 vs. 2032
- Figure 82: Global Clinical Biomarkers Market (Contract Research Organizations (CROs)), $Million, 2021-2032
- Figure 83: Global Clinical Biomarkers Market (Research and Academic Laboratories), $Million, 2021-2032
- Figure 84: Global Clinical Biomarkers Market (Diagnostic Centers), $Million, 2021-2032
- Figure 85: Global Clinical Biomarkers Market (Biopharmaceutical and Biotech Companies), $Million, 2021-2032
- Figure 86: Global Clinical Biomarkers Market (Other End Users), $Million, 2021-2032
- Figure 87: Global Clinical Biomarkers Market Snapshot (by Region), $Million, 2021-2032
- Figure 88: Global Clinical Biomarkers Market (by Region), $Million, 2021-2032
- Figure 89: Global Clinical Biomarkers Market (by Region), $Million, 2021 and 2032
- Figure 90: North America Clinical Biomarkers Market, $Million, 2021-2032
- Figure 91: North America: Market Dynamics
- Figure 92: North America Clinical Biomarkers Market (by Country), $Million, 2021-2032
- Figure 93: U.S. Clinical Biomarkers Market, $Million, 2021-2032
- Figure 94: Canada Clinical Biomarkers Market, $Million, 2021-2032
- Figure 95: Europe Clinical Biomarkers Market, $Million, 2021-2032
- Figure 96: Europe: Market Dynamics
- Figure 97: Europe Clinical Biomarkers Market (by Country), $Million, 2021-2032
- Figure 98: Germany Clinical Biomarkers Market, $Million, 2021-2032
- Figure 99: Share of Cancer Cases in Germany, 2020
- Figure 100: France Clinical Biomarkers Market, $Million, 2021-2032
- Figure 101: U.K. Clinical Biomarkers Market, $Million, 2021-2032
- Figure 102: Italy Clinical Biomarkers Market, $Million, 2021-2032
- Figure 103: Spain Clinical Biomarkers Market, $Million, 2021-2032
- Figure 104: Rest-of-Europe Clinical Biomarkers Market, $Million, 2021-2032
- Figure 105: Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032
- Figure 106: Asia-Pacific Clinical Biomarkers Market (by Country), $Million, 2021-2032
- Figure 107: Asia-Pacific: Market Dynamics
- Figure 108: China Clinical Biomarkers Market, $Million, 2021-2032
- Figure 109: India Clinical Biomarkers Market, $Million, 2021-2032
- Figure 110: Japan Clinical Biomarkers Market, $Million, 2021-2032
- Figure 111: South Korea Clinical Biomarkers Market, $Million, 2021-2032
- Figure 112: Australia Clinical Biomarkers Market, $Million, 2021-2032
- Figure 113: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032
- Figure 114: Latin America Clinical Biomarkers Market, $Million, 2021-2032
- Figure 115: Latin America: Market Dynamics
- Figure 116: Latin America Clinical Biomarkers Market (by Country), $Million, 2021-2032
- Figure 117: Brazil Clinical Biomarkers Market, $Million, 2021-2032
- Figure 118: Mexico Clinical Biomarkers Market, $Million, 2021-2032
- Figure 119: Rest-of-Latin America Clinical Biomarkers Market, $Million, 2021-2032
- Figure 120: Rest-of-the-World) Clinical Biomarkers Market, $Million, 2021-2032
- Figure 121: Total Number of Companies Profiled
- Figure 122: Abbott.: Product Portfolio
- Figure 123: Abbott.: Overall Financials, $Million, 2019-2021
- Figure 124: Abbott.: Revenue (by Segment), $Million, 2019-2021
- Figure 125: Abbott.: Revenue (by Region), $Million, 2019-2021
- Figure 126: Abbott.: R&D Expenditure, $Million, 2019-2021
- Figure 127: Agilent Technologies, Inc.: Product Portfolio
- Figure 128: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
- Figure 129: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 130: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 131: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 132: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 133: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
- Figure 134: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 135: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 136: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 137: Illumina, Inc.: Product Portfolio
- Figure 138: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 139: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 140: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 141: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 142: PerkinElmer Inc.: Product Portfolio
- Figure 143: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
- Figure 144: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 145: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 146: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 147: QIAGEN N.V.: Product Portfolio
- Figure 148: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
- Figure 149: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
- Figure 150: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
- Figure 151: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 152: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 153: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
- Figure 154: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 155: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 156: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 157: NeoGenomics Laboratories: Service Portfolio
- Figure 158: NeoGenomics Laboratories: Overall Financials, $Million 2019-2021
- Figure 159: NeoGenomics Laboratories: Revenue (by Segment), 2019-2021
- Figure 160: NeoGenomics Laboratories: R&D Expenditure, 2019-2021
- Figure 161: Charles River Laboratories: Service Portfolio
- Figure 162: Charles River Laboratories: Overall Financials, $Million, 2019-2021
- Figure 163: Charles River Laboratories: Revenue (by Segment), $Million, 2019-2021
- Figure 164: Charles River Laboratories.: Revenue (by Region), $Million, 2019-2021
- Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
- Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
- Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
- Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
- Figure 170: Quest Diagnostics Incorporated, Inc.: Service Portfolio
- Figure 171: Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021
- Figure 172: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2019-2021
- Figure 173: Enzo Biochem Inc.: Product Portfolio
- Figure 174: Enzo Biochem Inc.: Overall Financials, $Million, 2019-2021
- Figure 175: Enzo Biochem Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 176: Enzo Biochem Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 177: Enzo Biochem Inc.: R&D Expenditure, 2019-2021
- Figure 178: ALCEN.: Service Portfolio
- Figure 179: Myriad Genetics, Inc.: Service Portfolio
- Figure 180: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
- Figure 181: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 182: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 183: CENTOGENE N.V.: Service Portfolio
- Figure 184: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
- Figure 185: CENTOGENE N.V.: Revenue (by Segment), $Million, 2019-2021
- Figure 186: CENTOGENE N.V.: Revenue (by Region), $Million, 2019-2021
- Figure 187: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 188: bioMérieux S.A.: Product Portfolio
- Figure 189: bioMérieux S.A.: Overall Financials, $Million, 2019-2021
- Figure 190: bioMérieux S.A.: Revenue (by Segment), $Million, 2019-2021
- Figure 191: bioMérieux S.A.: Revenue (by Region), $Million, 2019-2021
- Figure 192: Arsenal Capital Partners: Services Portfolio
- Figure 193: Novogene Co., Ltd.: Service Portfolio
- Figure 194: Q2 Solutions: Service Portfolio
- Figure 195: Caris Life Sciences: Service Portfolio
- Figure 196: Broad Institute: Service Portfolio
- Figure 197: Personalis Inc.: Service Portfolio
- Figure 198: Personalis Inc.: Overall Financials, $Million, 2019-2021
- Figure 199: Personalis Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 200: Azenta Life Sciences: Service Portfolio
- Figure 201: Discovery Life Sciences: Service Portfolio
- Figure 202: BGI: Service Portfolio
- Figure 203: Eurofins Scientific: Service Portfolio
- Figure 204: Eurofins Scientific: Overall Financials, $Million, 2019-2021
- Figure 205: Eurofins Scientific: Revenue (by Region), $Million, 2019-2021
- Figure 206: Becton, Dickinson and Company: Product Portfolio
- Figure 207: Becton, Dickinson and Company: Overall Financials, $Million, 2019-2021
- Figure 208: Becton, Dickinson and Company: Revenue (by Region), $Million, 2019-2021
- Figure 209: Becton, Dickinson and Company: R&D Expenditure, $Million, 2019-2021
- List of Tables
- Table 1: COVID-19 Impact on Global Clinical Biomarkers Market
- Table 2: Key Player Initiatives
- Table 3: Pricing List of Product/Service
- Table 4: List of Product/Service and its Technology
- Table 5: Global Clinical Biomarkers Market: Key Players Patent Portfolio
- Table 6: Example of Efficacy Biomarker
- Table 7: Examples of Diagnostic Biomarker
- Table 8: Examples of Prognostic Biomarker
- Table 9: Examples of Safety Biomarker
- Table 10: Example of Clinical Biomarker Service
- Table 11: Next-Generation Sequencing-Based Clinical Biomarker Products
- Table 12: Polymerase Chain Reaction-Based Clinical Biomarker Products
- Table 13: Immunohistochemistry (IHC)-Based Clinical Biomarker Products
- Table 14: ELISA-Based Clinical Biomarker Products
- Table 15: Companies Offering Other Technologies-Based Products
- Table 16: Example of Cancer Biomarker
- Table 17: Example of Cardiac Biomarker
- Table 18: Example of Neurological Biomarker
- Table 19: Examples of Infectious Disease Biomarker
- Table 20: Estimated Cancer Deaths in California, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
